654 related articles for article (PubMed ID: 26267817)
21. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
Tremblay CL; Rouleau D; Fortin C; Toma E; Sylla M; Cyr L; Cote S; Baz M; Sampalis J; Trautman L; Sékaly RP; Boivin G
Vaccine; 2011 Feb; 29(7):1359-63. PubMed ID: 21185423
[TBL] [Abstract][Full Text] [Related]
22. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
[TBL] [Abstract][Full Text] [Related]
23. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
[TBL] [Abstract][Full Text] [Related]
24. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
Leroux-Roels I; Vets E; Freese R; Seiberling M; Weber F; Salamand C; Leroux-Roels G
Vaccine; 2008 Dec; 26(51):6614-9. PubMed ID: 18930093
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
[TBL] [Abstract][Full Text] [Related]
26. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.
Sun P; Crum-Cianflone NF; Defang G; Williams M; Ganesan A; Agan BK; Lalani T; Whitman T; Brandt C; Burgess TH
Vaccine; 2017 Oct; 35(45):6103-6111. PubMed ID: 28987439
[TBL] [Abstract][Full Text] [Related]
28. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
29. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
[TBL] [Abstract][Full Text] [Related]
31. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.
Kang K; Han S; Hong T; Jeon S; Paek J; Kang JH; Yim DS
Yonsei Med J; 2016 Nov; 57(6):1354-60. PubMed ID: 27593862
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal analysis of the peripheral B cell repertoire reveals unique effects of immunization with a new influenza virus strain.
Cortina-Ceballos B; Godoy-Lozano EE; Téllez-Sosa J; Ovilla-Muñoz M; Sámano-Sánchez H; Aguilar-Salgado A; Gómez-Barreto RE; Valdovinos-Torres H; López-Martínez I; Aparicio-Antonio R; Rodríguez MH; Martínez-Barnetche J
Genome Med; 2015 Nov; 7():124. PubMed ID: 26608341
[TBL] [Abstract][Full Text] [Related]
35. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.
Ansaldi F; Valle L; de Florentiis D; Parodi V; Murdaca G; Bruzzone B; Durando P; Setti M; Icardi G
Hum Vaccin Immunother; 2012 Aug; 8(8):1048-52. PubMed ID: 22832261
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
[TBL] [Abstract][Full Text] [Related]
37. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.
Soonawala D; Rimmelzwaan GF; Gelinck LB; Visser LG; Kroon FP
PLoS One; 2011 Jan; 6(1):e16496. PubMed ID: 21304982
[TBL] [Abstract][Full Text] [Related]
38. Relation of activation-induced deaminase (AID) expression with antibody response to A(H1N1)pdm09 vaccination in HIV-1 infected patients.
Cagigi A; Pensieroso S; Ruffin N; Sammicheli S; Thorstensson R; Pan-Hammarström Q; Hejdeman B; Nilsson A; Chiodi F
Vaccine; 2013 Apr; 31(18):2231-7. PubMed ID: 23499520
[TBL] [Abstract][Full Text] [Related]
39. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.
Gaglani M; Spencer S; Ball S; Song J; Naleway A; Henkle E; Bozeman S; Reynolds S; Sessions W; Hancock K; Thompson M
J Infect Dis; 2014 Jun; 209(11):1705-14. PubMed ID: 24363436
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients.
Torii Y; Kimura H; Ochi N; Kaneko K; Ando H; Kiuchi T; Ito Y
Vaccine; 2011 Jun; 29(25):4187-9. PubMed ID: 21513762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
